Lead Product(s) : Polyferon
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : Polyferon
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyferon
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : North-Western State Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 04, 2021
Lead Product(s) : Polyferon
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : North-Western State Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyferon
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ossium Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : Polyferon
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ossium Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyferon
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 13, 2017
Lead Product(s) : Polyferon
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 25, 2015
Lead Product(s) : Polyferon
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Biomerieux
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 05, 2011
Lead Product(s) : Polyferon
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Biomerieux
Deal Size : Inapplicable
Deal Type : Inapplicable